Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation

Ying Dong1,2, Erik A. Bey1,2, Long-Shan Li1,2, Wareef Kabbani3, Jingsheng Yan4, Xian-Jin Xie4, Jer-Tsong Hsieh5, Jinming Gao1, and David A. Boothman1,2

Abstract

The clinical experimental agent, β-lapachone (β-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism. In this study, we analyzed the mechanism to determine whether β-lap may warrant clinical evaluation as a radiosensitizer. β-Lap killed prostate cancer cells by NAD(P)Hquinone oxidoreductase 1 (NQO1) metabolic bioactivation, triggering a massive induction of reactive oxygen species, irreversible DNA single-strand breaks (SSB), poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, NAD+/ATP depletion, and μ-calpain–induced programmed necrosis. In combination with ionizing radiation (IR), β-lap radiosensitized NQO1+ prostate cancer cells under conditions where nontoxic doses of either agent alone achieved threshold levels of SSBs required for hyperactivation of PARP-1. Combination therapy significantly elevated SSB level, γ-H2AX foci formation, and poly(ADP-riboseylation) of PARP-1, which were associated with ATP loss and induction of μ-calpain–induced programmed cell death. Radiosensitization by β-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ. In a mouse xenograft model of prostate cancer, β-lap synergized with IR to promote antitumor efficacy. NQO1 levels were elevated in ∼60% of human prostate tumors evaluated relative to adjacent normal tissue, where β-lap might be efficacious alone or in combination with radiation. Our findings offer a rationale for the clinical utilization of β-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO1, offering a potentially synergistic targeting strategy to exploit PARP-1 hyperactivation. Cancer Res; 70(20); 8088–96. ©2010 AACR.

Introduction

Prostate cancer is the most common noncutaneous cancer in men in the United States. It occurs with the highest incidence (25%) of all cancers and is the second leading cause of cancer-related death in men (1). Radiation therapy [X-ray therapy (XRT)] using fractionated low doses of ionizing radiation (IR) is the most heavily used therapeutic method for treating primary prostate cancers. However, traditional external beam fractionated XRT using total IR doses of <68 Gy have only limited curative potential for locally advanced human prostate cancers are in great demand.

β-Lapachone (β-lap; 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione; also known as Arq 501), a novel antitumor quinone, has shown promise alone as a tumor-selective chemotherapeutic agent in cancers that overexpress endogenous NAD(P)H:quinone oxidoreductase-1 (NQO1; E.C. 1.6.99.2), a two-electron oxidoreductase. We previously showed that NQO1 metabolized β-lap through a futile cycle, with the parent quinone converted to a highly unstable hydroquinone form, utilizing dramatic levels of NAD(P)H. As a result, high levels of reactive oxygen species (ROS) are created, causing DNA lesions in NQO1+ cells (5–7). At LD90 and higher doses of β-lap (∼4 μmol/L), poly(ADP-ribose) polymerase-1 (PARP-1), a DNA damage sensor, is hyperactivated and extensive NAD+/ATP depletion ensues. PARP-1 hyperactivation required rapid Ca2+ release from endoplasmic reticulum stores, a result of ROS formation (8). Subsequently, loss of NAD+/ATP results in influx of Ca2+, leading to the activation and nuclear translocation of μ-calpain. Activation of μ-calpain causes a unique caspase-independent programmed necrotic cell death (8, 9). Importantly, β-lap killing of cancer cells is NQO1 specific and independent of cell cycle status, caspase activities, and...
Rb or p53 status (6, 7, 10–12). Because NQO1 is highly expressed in many human cancers, including prostate, lung, pancreatic, and breast cancers, β-lap has become an attractive agent for tumor-selective cancer chemotherapy.

PARP-1 is an abundant nuclear enzyme essential for repair of DNA single-strand breaks (SSB) and an important damage sensor, for which numerous groups are developing inhibitors (13–15), particularly after its identification as a synthetic lethal target in BRCA1/2 breast cancers (16, 17). PARP-1 is essential for base excision repair (BER), SSB, and possibly other DNA repair processes (18, 19). PARP-1 is activated after binding DNA strand breaks and uses NAD⁺ as a substrate to form long branched polymers of poly(ADP-ribose) (PAR). PARP-1- mediated poly(ADP-ribosylation) recruits various nuclear acceptor proteins, such as XRCC1, histones, and PARP-1 itself, to assemble other repair complexes to execute DNA repair [i.e., BER, SSB, and double-strand break (DSB) repair]. However, in response to excessive DNA damage, PARP-1 can be hyperactivated, converting its DNA repair capacity to initiation of programmed necrosis, due to dramatic NAD⁺ and ATP depletions. PARP-1 hyperactivation and programmed necrosis have been documented in several cellular responses, including ischemia-reperfusion, myocardial infarction, and severe ROS-induced injury (20). To date, however, the only cytotoxic agent able to harness this cell death pathway in a tumor-selective manner and at clinically relevant doses is β-lap (6, 21).

We previously showed that β-lap was an efficient radiosensitizer of specific cancer cells when given immediately after or during IR in vitro (22, 23). However, these studies stalled due to a lack of knowledge about the mechanism of action of the agent and an inability to efficaciously deliver the drug. Based on our recent elucidation of the mechanism of action of β-lap as a single agent (8, 9), we hypothesized that PARP-1 hyperactivation was a key factor mediating synergy between sublethal doses of IR and β-lap. Here, we show for the first time that PARP-1 hyperactivation is the principal determinant governing β-lap–radiosensitizing effects in NQO1⁺ human prostate cancer cells, causing early and rapid PAR-modified PARP-1 accumulation and synergistic ATP loss after IR + β-lap treatments. Along with dicoumarol (a specific inhibitor of NQO1), DPQ (a specific PARP-1 inhibitor) blocked dramatic ATP depletion and apoptosis, confirming an essential role of NQO1-dependent PARP-1 hyperactivation in mediating synergy between these two agents. Antitumor studies using PC-3 xenografts that have endogenously elevated NQO1 levels in athymic mice showed significantly enhanced antitumor efficacy using various combined sublethal doses of β-lap + IR. Thus, β-lap treatment in combination with XRT represents the first effective tumor-selective therapy that exploits PARP-1 hyperactivation for the treatment of cancers that have elevated NQO1 levels.

Materials and Methods

Chemicals and reagents

β-Lap, synthesized by Dr. Bill Bornmann (M.D. Anderson, Houston, TX), was dissolved in DMSO at 47 mmol/L, and concentrations were verified by spectrophotometry. Hoechst 33258, hydrogen peroxide (H₂O₂), staurosporine, cytochrome c, etoposide, DPQ (3,4-dihydro-[4-(1-piperidinyl)butoxy]-1 (2H)-isoquinoline), and dicoumarol (24) were purchased from Sigma-Aldrich.

Cell culture

PC-3, DU145, and LNCaP human prostate cancer cells were originally obtained from Dr. George Wilding (University of Wisconsin-Madison). PC-3 and DU145 cells were grown in RPMI 1640 (Invitrogen) with 5% bovine serum (FBS) and LNCaP cells were grown in DMEM (Invitrogen) with 10% FBS. Cells were cultured at 37°C in a 5% CO₂-95% air humidified atmosphere and were free of Mycoplasma.

Western immunoblotting

Whole-cell extracts were prepared, proteins were separated by SDS-PAGE, and Western blots were developed using SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific) and exposed using autoradiography film (Denville Scientific, Inc.). An antihuman NQO1 antibody was kindly provided to us by Dr. David Ross (University of Colorado Health Science Center, Denver, CO) and used at 1:5,000 dilution overnight at 4°C. Both PAR (BD Pharmingen) and γH₂AX (Upstate) antibodies were used at 1:2,000 and 1:1,000 dilutions, respectively. β-Actin or α-tubulin levels were used as loading controls.

Relative survival assays

Relative survival was assessed by DNA content and colony forming assays as described (25). Briefly, for DNA content, cells were seeded at 5 × 10⁴ per well in 48-well plates and allowed to attach overnight. Cells were then mock treated or treated with various doses of β-lap (for 2 hours) in the presence or absence of dicoumarol as indicated. Drug-free medium was then added and cells were allowed to grow for 5 to 7 days until control cells reached ~100% confluence. DNA content was then determined by Hoechst 33258 staining and fluorescence detection using a plate reader (Perkin-Elmer; ref. 21). Relative survival assays after combined treatment were confirmed by colony-forming ability assays (25). Results were reported as mean ± SE from at least three independent experiments.

Total and oxidized glutathione assays

Disulfide and total glutathione (GSH and GSSG, respectively) levels were determined using a spectrophotometric recycling assay (26). After treatments, whole-cell homogenates were prepared (11). Data were expressed as %GSSG/total, normalized to protein content, following the procedure of Lowry and colleagues (27). Data were shown as mean ± SE of experiments performed at least three times.

Alkaline and neutral comet assays

DNA lesions, including total base damage, DSBs, and SSBs, versus DSBs were assessed using single-cell gel electrophoretic comet assays under alkaline or neutral conditions, respectively (Trevigen). Slides were stained with SYBR Green and visualized using a Nikon Eclipse TE2000-E fluorescence microscope.
microscope. Digital photomicrographs were taken and comet tail lengths quantified using NIH Image J software. Each data point represented the average of 100 cells ± SE, and data were representative of experiments performed in triplicate.

**Nucleotide analyses**

Changes in intracellular NAD⁺ levels were measured (6) and levels were expressed as percent treated divided by control (% T/C) ± SE from at least three individual experiments. ATP levels were analyzed from whole-cell extracts using CellTiter-Glo Luminescent Cell Viability Assays (Promega) following the manufacturer’s instructions. Data were graphed as mean ± SE from at least three independent experiments in triplicate.

**Apoptotic assays**

Apoptosis was quantified using ApoDirect [terminal deoxyribonucleotidyl transferase–mediated dUTP nick end labeling (TUNEL)] assays from BD Pharmingen (21). Samples were analyzed by using a FC-500 flow cytometer (Beckman Coulter Electronics) and Elite acquisition software. Data were expressed as mean ± SE from at least three independent experiments.

**Antitumor efficacy**

Athymic nu/nu mice were purchased from Charles River Laboratories International, Inc. All animals were housed in a pathogen-free facility with 24-h access to food and water. Experimental protocols were approved by the institutional Animal Care and Use Committee at the University of Texas Southwestern. PC-3 cells (5 × 10⁴) were s.c. injected into the right thighs of athymic nude mice, and tumor volumes were measured by caliper (length × width × width/2) every other day. Mice were then randomly grouped with no statistical differences in tumor sizes among the six groups. Mice were then mock treated or exposed to various IR doses followed immediately by treatment with various doses (10–30 mg/kg) of β-lap-HPβ-CD or HPβ-CD. When used, various doses of IR were given locally first to tumor sites with whole-body shielding. Mice were then mock treated or exposed to various IR dosed followed immediately by treatment with various doses (10–30 mg/kg) of β-lap-HPβ-CD or HPβ-CD. When used, various doses of IR were given locally first to tumor sites with whole-body shielding. Mice were then mock treated or exposed to various IR dosed followed immediately by treatment with various doses (10–30 mg/kg) of β-lap-HPβ-CD or HPβ-CD. When used, various doses of IR were given locally first to tumor sites with whole-body shielding.

**Statistical analyses**

For relative survival, different IR + β-lap combinations were fit with simple multitarget models in SigmaPlot for Windows version 11.0. For synergy, a statistical definition of synergy (28) was used and calculations were performed by fitting experimental data with the Machado and Robinson model using the R code (29). The equitoxic doses listed in Table 1 were calculated using the parameters of the model of Machado and Robinson obtained in fitting. Regression analyses of tumor growth profiles in vivo in six tested groups were analyzed using a mixed model approach with AR (1) correlation structures. Log-rank tests were applied to survival analyses (Kaplan-Meier curves). In general, P values of ≤0.05 using two-sided Student’s t test were considered significant. All statistical analyses were performed using SAS 9.1 Service Pack 4.

### Results

**β-Lap induces prostate cancer cell death through NQO1-induced ROS formation and SSBs**

Our immunohistochemical analyses of human prostate tumor and associated normal tissue revealed that ~60% of these cancers had elevated NQO1 levels (Supplementary Fig. S1). Using human PC-3 prostate cancer cells that express high levels of endogenous NQO1, we showed that the cytotoxic effects of β-lap were NQO1 dependent (inhibited by dicoumarol Fig. 1A). This was confirmed in DU145 and in NQO1-proficient (NQO1⁺) versus NQO1-deficient (NQO1⁻) LNCaP cells (Supplementary Fig. S2). Importantly, only ~120 minutes of exposure to 4 μmol/L β-lap was sufficient to achieve maximal cytotoxicity (Fig. 1A), where significant levels of glutathione were oxidized (note rapid and elevated levels of %GSSG in 20–30 minutes; Fig. 1B), suggesting dramatic ROS formation. Dramatic increases in SSBs were seen by alkaline comet assays, but DSBs, as assessed by neutral comet assays, were not noted (Fig. 1C and D). Similar results were found using DU145 and NQO1⁺ LNCaP cells (Supplementary Fig. S2). In contrast, NQO1⁻ LNCaP cells were not responsive to β-lap as described (5).

The DNA damage and repair responses of β-lap-treated NQO1-expressing PC-3 cells were compared with their responses after IR treatment (Fig. 1E and F). Extensive DNA lesions were noted in PC-3 cells after exposure to 4 μmol/L β-lap, equivalent to 20 Gy by alkaline assays. However, neutral comet assays revealed DSBs after IR, but not after β-lap exposure (not shown). Exposure of PC-3 cells to IR (20 Gy)

### Table 1. Equitoxic doses comparing single to combined treatment in PC-3 cells

<table>
<thead>
<tr>
<th>IR (Gy)</th>
<th>β-Lap (μmol/L)</th>
<th>Equivalent dose of IR (Gy)</th>
<th>Equivalent dose of β-lap (μmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>0.6</td>
<td>1</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
<td>0.9</td>
<td>2</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>1.2</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>4.1</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>1.9</td>
<td>5.5</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>2.3</td>
<td>6.9</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>2.5</td>
<td>7.9</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>2.9</td>
<td>9.6</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>3.2</td>
<td>11.2</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>3.5</td>
<td>12.5</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>3.9</td>
<td>14.2</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>4.2</td>
<td>16</td>
</tr>
</tbody>
</table>

NOTE: Values of equivalent doses were calculated using parameters obtained from fitting the data from three independent experiments done in triplicate with Machado’s model.
resulted in DNA damage that was quickly repaired within 1 hour after treatment, whereas DNA damage created by 4 μmol/L β-lap was not repaired, but escalated over the 4-hour time period assessed, suggesting repair inhibition.

**PARP-1 hyperactivation mediates β-lap–induced programmed cell death**

Exposure of PC-3 cells to lethal doses of β-lap (Fig. 2A) caused extensive PARP-1 hyperactivation, with significant PAR accumulation within 10 to 20 minutes that was blocked by dicoumarol (Fig. 2B). Loss of PAR formation in β-lap–treated PC-3 cells, which was noted from 40 to 60 minutes, was most likely due to NAD’ substrate depletion (Fig. 2C), as well as functional PAR glycohydrolase (30). PARP-1 hyperactivation was accompanied by dramatic NAD’ and ATP losses as a function of (a) time (Fig. 2C), where metabolite levels were exhausted within 120 minutes of β-lap exposure, and (b) dose, where loss of ATP corresponded well with cytotoxicity (Fig. 2A and D). Loss of intracellular nucleotide levels (NAD’/ATP) and lethality of β-lap–treated PC-3 cells were blocked by dicoumarol (40 μmol/L). Dicoumarol also prevented PARP-1 hyperactivation, NAD’ and ATP losses, and cytotoxicity in DU145 cells after β-lap exposure (Supplementary Fig. S3).

**Synergy between IR and β-lap is mediated by DNA damage, reaching a threshold for PARP-1 hyperactivation**

We previously reported that the combination of IR and β-lap synergistically killed specific cancer cells (31); however,
the mechanism of synergy was not elucidated. PC-3 cells were treated with single doses of IR (1–3 Gy) followed by exposure to low, nontoxic doses of β-lap (1–3 μmol/L). Synergy was noted with all IR and β-lap combinations tested (Fig. 3A), corresponding to synergistic increases of PAR levels after combined treatments, but not after single agent exposures. For example, dramatic PAR formation in PC-3 cells treated with 1 Gy + 3 μmol/L β-lap was noted at 60 minutes, with no apparent PAR levels in cells after each agent alone (Fig. 3B). Similar responses were noted in NQO1+ LNCaP and DU145 cells, but not in genetically matched NQO1− LNCaP cells (Supplementary Figs. S4A and S5B, respectively). Synergy was prevented by dicoumarol in NQO1+ prostate cancer cells, corresponding to the formation of DNA lesions (noted by alkaline comet and γH2AX foci formation) that presumably reached threshold levels required for PARP-1 hyperactivation (Supplementary Fig. S5). Synergy between IR and β-lap in PC-3 cells was accompanied by dramatic losses of ATP (Fig. 3C and D, synergy between 2 or 3 Gy and 3 μmol/L β-lap) and NAD+ (not shown). Importantly, synergistic losses of ATP in PC-3 cells following 2 or 3 Gy + 3 μmol/L β-lap were prevented by pre- and co-treating the cells with DPQ, a specific PARP-1 inhibitor (Fig. 3C and D, respectively) that prevented cell death induced by β-lap alone in various endogenously overexpressing NQO1 cancer cells (6, 21). Synergistic ATP loss was also observed in NQO1+ LNCaP cells (Supplementary Fig. S4B).
Synergy between IR and β-lap exposures involves atypical PARP-1 cleavage and TUNEL+ programmed necrosis

Loss of survival as a result of β-lap treatment correlated well with TUNEL+ apoptotic responses (32). The synergistic cytotoxic responses of NQO1+ PC-3 cells after IR + β-lap treatment were confirmed by analyzing apoptosis (Fig. 4A). Treatment of PC-3 cells with 1 to 3 Gy, each in combination with 2 μmol/L β-lap, resulted in significant increases in apoptotic cells within 72 hours (Fig. 4A), corresponding directly to loss of colony forming ability (Fig. 3A). Indeed, all combination therapies of IR with β-lap (Table 1) reveal synergy at these low doses of each agent. For example, treatment of PC-3 cells with nonlethal agents (alone) in combination with IR (i.e., 1 Gy + 1 μmol/L β-lap) was the same as treating cells with a lethal dose of 4 μmol/L β-lap. Similar responses were noted in NQO1+ LNCaP cells, in which synergistic levels of apoptosis and atypical PARP-1 cleavage at 72 hours after treatment were noted (Supplementary Fig. S6). Synergy between IR and β-lap was prevented by DPQ (Fig. 4A) or dicoumarol, and was not observed in NQO1−LNCaP cells.

Efficacy in vivo of the combination of IR and β-lap

To date, the efficacy of β-lap against human prostate cancer xenografts expressing elevated levels of endogenous NQO1 has not been shown. Using the current clinical formulation of the drug (i.e., Arq 501) conjugated with HPβ-CD, we showed significant efficacy of β-lap-HPβ-CD when administered at 10 or 20 mg/kg in combination with 2-Gy fractions of IR (Fig. 5A). Mice (five per group) bearing PC-3 xenografts...
with an average tumor volume of ∼350 mm³ were exposed to five doses of IR alone, β-lap-HPβ-CD alone, or IR + β-lap-HPβ-CD combinations every other day between days 1 and 9. All drug treatments were administered by i.v. injection. Treatment of mice with β-lap-HPβ-CD at 10 or 20 mg/kg exhibited neither antitumor efficacy nor morbidity or mortality. Although mice treated with 2-Gy fractions (five treatments, every other day) resulted in significant tumor growth delay (average, 26 days; Fig. 5; Supplementary Fig. S7A and Supplementary Table S1), combinations of 2-Gy IR with 10 or 20 mg/kg β-lap-HPβ-CD resulted in significant tumor regression beyond the additive levels with IR or β-lap-HPβ-CD treatments alone. Ninety percent (9 of 10) of animals exposed to IR + 10 or 20 mg/kg β-lap-HPβ-CD were “apparently cured,” showing no further tumor growth for up to 150 days (Fig. 5B; Supplementary Table S1). In contrast, 90% PC-3-bearing mice treated with β-lap-HPβ-CD alone (10 or 20 mg/kg) died within 40 days, similar to control mice treated with vehicle (HPβ-CD) alone. Mice treated with IR (2 Gy) alone showed an obvious delay in tumor growth (Fig. 5A); however, all mice eventually died (sacrificed when tumor volumes were >10% of their weight). Finally, although treatment of mice with 2 Gy + 30 mg/kg β-lap-HPβ-CD resulted in statistically equivalent tumor growth delay and “apparent cures” (Supplementary Table S1), we noted that the dose was close to the maximum tolerated dose of the drug (Supplementary Fig. S7B). Collectively, we treated 15 mice (3 × 5 mice per group) with 2 Gy + 10 to 30 mg/kg β-lap-HPβ-CD were identical.

Discussion

In general, there is a great need for improved combination therapy, where XRT is combined with tumor-selective therapies to increase antitumor efficacy, while simultaneously decreasing normal tissue toxicity. For XRT, the intrinsic radioresistance of many tumors poses significant clinical obstacles, limiting efficacy (33). Since the first stereotactic body radiotherapy (SBRT) was developed in 1991, the method has been refined to decrease high doses of IR used in local primary or focal metastatic lesions (34, 35). Recently,
hypofractionated SBRT delivered by CyberKnife using three to five fractionated high-dose XRT resulted in minimal toxicity, lowering short-term PSA and preserving normal tissue function in men with localized prostate cancer (36, 37). However, such SBRT regimens are not suited to treat metastatic disease, and long-lasting normal tissue toxicity is still problematic. Our data showed that XRT combined with β-lap post-treatments selectively killed NQO1+ prostate cancer cells, offering a strategy to use lower efficacious doses of IR for targeted therapy while simultaneously eliminating prostate cancer micrometastases. This therapy should be applicable to all cancers that have elevated levels of NQO1.

β-Lap is the only agent that selectively kills tumor cells by PARP-1-mediated, μ-calpain–directed programmed necrosis at clinically relevant doses. Detailed knowledge of its mechanism of action can be exploited for improving XRT of tumors with elevated NQO1 levels. The tumor-selective nature of the therapy, for those individuals with elevated NQO1 levels, should allow reduced IR exposures while achieving improved antitumor efficacy and simultaneously avoiding normal tissue complications. Importantly, resistance to β-lap–induced, NQO1-directed antitumor cytotoxicity has not been noted to date (10, 12), most likely due to the diverse downstream effects of this drug in NQO1-containing cells, including dramatic alterations in nucleotide metabolism (i.e., NAD+/ATP losses), DNA damage, and loss of Ca2+ homeostasis.

DNA damage response pathways have become new and effective targets to potentiate XRT. Considerable interest has been focused on targeting PARP-1 to eliminate DNA repair and enhance the sensitivity of cancer cells to other DNA-damaging agents, including chemotherapeutic agents and IR (38–40). None of these approaches currently exploit PARP-1 hyperactivation, which requires a “threshold” of DNA lesions to activate a suicide pathway. Our data suggest that massive levels of ROS formed by β-lap lead to persistent base lesions that are ultimately converted to SSBs by BER, which, in turn, hyperactivate PARP-1. Due to dramatic NAD+/ATP losses, other repair processes that depend on energy are blocked, preventing repair of lethal DSBs created by IR. The delayed increase in γH2AX formation after PAR formation (Supplementary Fig. S2B) is consistent with PARP-1 break protection, followed by SSBs and eventually DSB formation detected by ATM, resulting in γH2AX foci formation.

Current phase I/II clinical trials of β-lap (i.e., Arq 501) were limited by high doses of HP-β-CD vehicle that caused hemolytic anemia, limiting efficacy. We show that nontoxic doses of β-lap-HP-β-CD can be delivered in combination with XRT for efficacious antitumor therapy of prostate cancers expressing endogenously elevated NQO1 levels. The efficacy of combination therapy was much greater than that of single regimens alone (Table 1). Synergy between IR and β-lap in vitro was determined using several applied models (28, 29, 41, 42), but the Machado model gave the most consistent results. Overall, the ability of β-lap to sensitize IR-exposed NQO1+ tumor cells relates to the higher DNA lesions created by the drug/radiation combination that meets a threshold level required for PARP-1 hyperactivation and synergistic cell death, consistent with prior findings (31).

Here, we show that lethal doses of β-lap alone or sublethal doses of IR + β-lap kill NQO1+ prostate cancer tumor cells as a result of extensive ROS formation, massive DNA damage, PARP-1 hyperactivation, and dramatic energy depletion (Figs. 1 and 2). Energy depletion, in turn, dramatically inhibits DNA repair. PAR formation was detected after combined IR + β-lap treatments, but not after single sublethal exposures of IR or β-lap alone in NQO1+ LNCaP cells. LNCaP NQO1− cells were not responsive (Supplementary Fig. S4A). Downstream, dramatic metabolic changes culminated in catastrophic Ca2+ homeostasis. Atypical PARP-1 cleavage was noted after combination therapy, but not after sublethal IR or β-lap single treatment alone, in NQO1+ human prostate cancer cells (Fig. 4B; Supplementary Fig. S6B), consistent with μ-calpain–mediated TUNEL+ programmed cell death responses after lethal doses of β-lap (6, 9). Because β-lap alone or XRT + β-lap combination therapy kills cells independent of cell cycle or p53 status, it represents a controllable synergistic therapy for slow-growing NQO1+ prostate cancer, as well as for non–small cell lung, pancreatic, and breast cancers, whose elevated NQO1 levels are more frequent and even greater than those of enzyme activities in associated normal tissue. Importantly, we show for the first time that XRT + β-lap-HP-β-CD caused significant long-term tumor regression with no tumor recurrence. The use of β-lap to synergize with IR (XRT) offers selectivity that can be rapidly individualized, such as for those prostate cancer patients whose NQO1 levels are elevated. Patients with easily detectable polymorphisms in NQO1 can be screened using blood-derived SNP analyses and excluded from treatment (21). Although efficacious, we theorize that improved drug delivery using milliroads for brachytherapy (43) or nanoparticle micelles (44) with XRT will further augment antitumor efficacy for the treatment of cancers with elevated NQO1 levels, such as for prostate cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the Tissue Procurement and Biostatistics Shared Resources, supported by the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center. This is C SCN #052 from the Cell Stress and Cancer Nanomedicine (CSCN) program. We are also grateful for support from the Robert and Virginia Payne endowment to D.A. Boothman. This work is dedicated to Ray Boothman (1928–2010).

Grant Support

National Cancer Institute/NIH grant 2 R01 CA102792-08, DoD grant W81XWH-06-1-0198 (D.A. Boothman), and DoD postdoctoral grant W81XWH-08-1-0 (Y. Dong).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 04/20/2010; revised 07/19/2010; accepted 08/08/2010; published OnlineFirst 10/12/2010.
Dong et al.

References


Downloaded from cancerres.aacrjournals.org on April 23, 2021. © 2010 American Association for Cancer Research.
Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation

Ying Dong, Erik A. Bey, Long-Shan Li, et al.

Cancer Res 2010;70:8088-8096. Published OnlineFirst October 12, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1418

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/10/11/0008-5472.CAN-10-1418.DC1

Cited articles
This article cites 43 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/20/8088.full#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/70/20/8088.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/70/20/8088.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.